Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11923116 | 0.81 | ACHE (0.59) | ACHE | |
| SCHEMBL5004281 | 0.80 | ACHE (0.39) | ACHE | |
| SCHEMBL3884111 | 0.79 | ACHE (0.45) | ACHE | |
| SCHEMBL18816748 | 0.77 | ACHE (0.36) | ACHETDP1MEN1GAAKMT2A | |
| SCHEMBL3882977 | 0.77 | MEN1 (0.31) | MEN1GAAKMT2A | |
| SCHEMBL3894832 | 0.77 | MEN1 (0.34) | TDP1MEN1GAAKMT2A | |
| SCHEMBL18452390 | 0.76 | EPHX2 (0.49) | ACHETDP1KMT2A | |
| SCHEMBL3884769 | 0.76 | — | — | |
| SCHEMBL18792724 | 0.76 | ACHE (0.35) | ACHETDP1MEN1GAAKMT2A | |
| SCHEMBL1883074 | 0.76 | ACHE (0.35) | ACHETDP1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566738-B2 | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use | XENOPORT, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080242723-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF SULFINIC ACIDS, METHODS OF SYNTHESIS, AND USE | XENOPORT, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20060111439-A1 | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242723-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF SULFINIC ACIDS, METHODS OF SYNTHESIS, AND USE | ASS1, APEH, ACMSD | ACHE 450/4885TDP1 1277/4885MEN1 4493/4885 |
| US-20060111439-A1 | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use | ASS1, APEH, ACMSD | ACHE 450/4885TDP1 1277/4885MEN1 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.